Two novel combination therapies of glioblastoma multiforme from a Cx43 perspective : studies of in vitro models
Author: Asklund, Thomas
Date: 2008-04-18
Location: Radiumhemmets föreläsningssal
Time: 09.30
Department: Institutionen för onkologi-patologi / Department of Oncology-Pathology
View/ Open:
thesis.pdf (721.9Kb)
Abstract
The group of patients suffering from the malignant brain tumour
glioblastoma multiforme (GBM) have a median survival of only about one
year. Thus, new treatment strategies are urgently needed.
Gap junctions are intercellular channels, permitting intercellular transfer of water soluble substances. They are vital for cellular homesostasis, proliferation and differentiation. Gap junctions are composed of multimeric proteins termed connexins (Cxs), of which Cx43 is the most ubiquitous. Cx43 serves as a tumour suppressor independent of its ability to form gap junctions.
Herpes simplex virus thymidine kinase (HSV-tk) mediated suicide gene therapy has shown promising results in preclinical research, but has as yet failed to prove clinical efficacy. Intriguingly, neural progenitor cells (NPCs) have shown tropism for intracranial tumours and could be exploited for improving the delivery of therapeutic genes or gene products. Epigenetic regulators, such as histone deacetylase inhibitors (HDACi) and receptor tyrosine kinase inhibitors (RTKIs), including gefitinib and vandetanib, have recently entered clinical trials.
In the present study, primary cultures of GBM cells were established and showed positivity for neuroepithelial markers. Additionally, they were Cx43 positive and functional gap junctions were demonstrated.
The bystander effect in the HSV-tk/ganciclovir (HSV-tk/GCV) suicide gene therapy system was attenuated by a specific gap junction inhibitor, AGA, showing that this phenomenon is dependent on gap junction coupling in glioma cells.
The HDAC inhibitor 4-phenylbutyrate (4-PB) up regulated Cx43 and enhanced gap junction communication (GJC), a strategy which could have potential for improving efficacy of suicide gene therapy. NPCs exposed to 4-PB also increased Cx43 expression and gap junction formation. This, together with the propensity of NPCs of tracking down tumour cells, could add a new dimension to gene therapy.
Cooperative antitumoural effects were evident in combination treatment of 4-PB and the RTKIs gefitinib and vandetanib. These RTKIs showed an up regulating effect on the tumour suppressor Cx43, which could show to be of importance in the downstream effects of RTKIs.
Gap junctions are intercellular channels, permitting intercellular transfer of water soluble substances. They are vital for cellular homesostasis, proliferation and differentiation. Gap junctions are composed of multimeric proteins termed connexins (Cxs), of which Cx43 is the most ubiquitous. Cx43 serves as a tumour suppressor independent of its ability to form gap junctions.
Herpes simplex virus thymidine kinase (HSV-tk) mediated suicide gene therapy has shown promising results in preclinical research, but has as yet failed to prove clinical efficacy. Intriguingly, neural progenitor cells (NPCs) have shown tropism for intracranial tumours and could be exploited for improving the delivery of therapeutic genes or gene products. Epigenetic regulators, such as histone deacetylase inhibitors (HDACi) and receptor tyrosine kinase inhibitors (RTKIs), including gefitinib and vandetanib, have recently entered clinical trials.
In the present study, primary cultures of GBM cells were established and showed positivity for neuroepithelial markers. Additionally, they were Cx43 positive and functional gap junctions were demonstrated.
The bystander effect in the HSV-tk/ganciclovir (HSV-tk/GCV) suicide gene therapy system was attenuated by a specific gap junction inhibitor, AGA, showing that this phenomenon is dependent on gap junction coupling in glioma cells.
The HDAC inhibitor 4-phenylbutyrate (4-PB) up regulated Cx43 and enhanced gap junction communication (GJC), a strategy which could have potential for improving efficacy of suicide gene therapy. NPCs exposed to 4-PB also increased Cx43 expression and gap junction formation. This, together with the propensity of NPCs of tracking down tumour cells, could add a new dimension to gene therapy.
Cooperative antitumoural effects were evident in combination treatment of 4-PB and the RTKIs gefitinib and vandetanib. These RTKIs showed an up regulating effect on the tumour suppressor Cx43, which could show to be of importance in the downstream effects of RTKIs.
List of papers:
I. Asklund T, Appelskog IB, Ammerpohl O, Langmoen IA, Dilber MS, Aints A, Ekström TJ, Almqvist PM (2003). "Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene." Exp Cell Res 284(2): 185-95
Pubmed
II. Asklund T, Appelskog IB, Ammerpohl O, Ekström TJ, Almqvist PM (2004). "Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells." Eur J Cancer 40(7): 1073-81
Pubmed
III. Khan Z, Akhtar M, Asklund T, Juliusson B, Almqvist PM, Ekström TJ (2007). "HDAC inhibition amplifies gap junction communication in neural progenitors: potential for cell-mediated enzyme prodrug therapy." Exp Cell Res 313(13): 2958-67. Epub 2007 May 22
Pubmed
IV. Asklund T, Marino A, Juhlin C, Sofiadis A, Khan Z, Larsson C, Henriksson R, Ekström TJ (2008). "Cooperative cytotoxicity by HDAC inhibitors and RTKIs: induction of Cx43 in GBM cells." (Submitted)
I. Asklund T, Appelskog IB, Ammerpohl O, Langmoen IA, Dilber MS, Aints A, Ekström TJ, Almqvist PM (2003). "Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene." Exp Cell Res 284(2): 185-95
Pubmed
II. Asklund T, Appelskog IB, Ammerpohl O, Ekström TJ, Almqvist PM (2004). "Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells." Eur J Cancer 40(7): 1073-81
Pubmed
III. Khan Z, Akhtar M, Asklund T, Juliusson B, Almqvist PM, Ekström TJ (2007). "HDAC inhibition amplifies gap junction communication in neural progenitors: potential for cell-mediated enzyme prodrug therapy." Exp Cell Res 313(13): 2958-67. Epub 2007 May 22
Pubmed
IV. Asklund T, Marino A, Juhlin C, Sofiadis A, Khan Z, Larsson C, Henriksson R, Ekström TJ (2008). "Cooperative cytotoxicity by HDAC inhibitors and RTKIs: induction of Cx43 in GBM cells." (Submitted)
Issue date: 2008-03-28
Rights:
Publication year: 2008
ISBN: 978-91-7357-536-2
Statistics
Total Visits
Views | |
---|---|
Two ...(legacy) | 769 |
Two ... | 109 |
Total Visits Per Month
November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | |
---|---|---|---|---|---|---|---|
Two ... | 1 | 0 | 0 | 8 | 0 | 0 | 0 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 359 |
thesis.pdf | 90 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 334 |
China | 77 |
Germany | 60 |
Sweden | 52 |
South Korea | 15 |
Hong Kong | 13 |
Russia | 12 |
Finland | 10 |
United Kingdom | 8 |
Ireland | 7 |
Top cities views
Views | |
---|---|
Sunnyvale | 41 |
Romeo | 39 |
Beijing | 27 |
Kiez | 17 |
Shenzhen | 17 |
Seoul | 14 |
Nürnberg | 11 |
Wong Chuk Hang | 8 |
Dublin | 7 |
Ashburn | 6 |